Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients | Zendy

Emma Taylor | Zendy; Mark Jones | Zendy; Matthew Hourigan | Zendy; David W. Johnson | Zendy; Devinder Gill | Zendy; Nicole M. Isbel | Zendy; Carmel M. Hawley | Zendy; Paula Marlton | Zendy; Maher K. Gandhi | Zendy; Scott B. Campbell | Zendy; Peter Mollee | Zendy

Open Access

Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients

Author(s) -

Emma Taylor,

Mark Jones,

Matthew Hourigan,

David W. Johnson,

Devinder Gill,

Nicole M. Isbel,

Carmel M. Hawley,

Paula Marlton,

Maher K. Gandhi,

Scott B. Campbell,

Peter Mollee

Publication year - 2015

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfv260

Subject(s) - medicine , immunosuppression , lymphoproliferative disorders , chemotherapy , renal transplant , post transplant lymphoproliferative disorder , transplantation , surgery , lymphoma , rituximab

The optimal reduction of immunosuppressive therapy (IST) in renal transplant patients with post-transplant lymphoproliferative disorders (PTLDs) is uncertain. As chemotherapy is immunosuppressive, IST may be stopped during this time without compromising graft function. Subsequent long-term reduction of IST reduces relapse risk, but may increase risk of graft rejection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research